Kornimate/medical-research-clean huggingface dataset:
perioperative rehabilitation therapy in patients undergoing liver transplantation

Conditions: Liver Transplantation; Sarcopenia

Summary: patients undergoing liver transplantation frequently experience a reduction in skeletal muscle mass, malnutrition, and decreased levels of physical activity. these complications can adversely affect early postoperative recovery and the therapeutic effect of the transplant. this clinical study aims to investigate the effects of nutritional supplementation and rehabilitation therapy on sarcopenia associated with liver transplantation in adults. the goal is to establish a comprehensive perioperative intervention strategy to reduce the incidence of postoperative sarcopenia and improve transplantation outcomes.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 70 years. 2. patients with end-stage liver disease who meet the criteria for liver transplantation (for liver cancer cases, only recipients meeting specific standards are included). 3. complete clinical information, including documented pre-transplant muscle status (e.g., preoperative ct scans and handgrip strength tests). 4. high compliance with treatment, fully capable of independent action or having at least one assistant. 5. no contraindications to the planned interventions. exclusion criteria: 1. presence of musculoskeletal disorders before transplantation, such as myositis, idiopathic muscle atrophy, or history of hip surgery within the past three months. 2. coexisting severe cardiovascular or cerebrovascular diseases, infectious diseases, or epilepsy. 3. liver transplantation due to autoimmune liver disease or drug-induced liver failure. 4. re-transplantation, multi-organ transplantation, living donor liver transplantation, split liver transplantation, or pediatric liver transplantation. 5. abo-incompatible liver transplantation. 6. incomplete clinical information. 7. difficulty in follow-up.

Keywords: liver transplantation sarcopenia branched-chain amino acids muscle rehabilitation
myotubular and centronuclear myopathy patient registry

Conditions: Myotubular Myopathy; Myotubular Myopathy 1; Myotubular (Centronuclear) Myopathy; Centronuclear Myopathy; Centronuclear Myopathy, X-Linked; X-linked Myotubular Myopathy

Summary: the myotubular and centronuclear myopathy patient registry (also referred to as the 'mtm and cnm registry') is an international, patient-reported database specific to these conditions. more details and online registration are available at www.mtmcnmregistry.org.

the myotubular and centronuclear myopathy (mtm \& cnm) patient registry is managed and operated by the john walton muscular dystrophy research centre at newcastle university, in partnership with the myotubular trust, and is part of the treat-nmd neuromuscular network. the registry has been developed in partnership with a number of leading neuromuscular researchers, and is jointly funded by the myotubular trust, muscular dystrophy uk and astellas gene therapies. participants register online and must provide consent before accessing the registry questionnaire. the clinical data and genetic or biopsy reports are provided by the participants and their doctors. the mtm \& cnm registry aims to: * help identify patients for relevant clinical trials as they become available. * encourage further research into myotubular and centronuclear myopathy. * provide researchers with specific patient information to support their research. * assist doctors and other health professionals by providing them with up-to-date information on managing myotubular and centronuclear myopathy, to help them deliver better standards of care for their patients. the investigators welcome the registration of: * all patients with a myotubular myopathy or centronuclear myopathy diagnosis, which has been confirmed via genetic testing or muscle biopsy. * any carrier females of x-linked myotubular myopathy, especially if they have manifested myotubular myopathy type symptoms. * any patient who is deceased, but who had a confirmed diagnosis. this is an online registry and is hosted on the rdrf (rare disease registry framework) by murdoch university. more details and online registration are available at www.mtmcnmregistry.org.

Eligibility criteria:
inclusion criteria: * patients with a myotubular myopathy or centronuclear myopathy diagnosis, which has been confirmed via genetic testing or muscle biopsy. * any carrier females of x-linked myotubular myopathy, especially if they have manifested myotubular myopathy type symptoms. * any patient who is deceased, but who had a confirmed diagnosis. exclusion criteria: - none

Keywords: registry patient registry myotubular centronuclear myopathy
exploring interactions between growth hormone and the microbiome

Conditions: Growth Hormone Deficiency

Summary: the goal of this study is to characterize the microbiome and metabolomics of children with growth hormone (gh) deficiency, prior gh treatment initiation and compare it to healthy children


Eligibility criteria:
inclusion criteria: * children with gh deficiency exclusion criteria: * turner syndrome * end state renal disease (esrd) * prader-willi syndrome * systemic illness * antibiotics/antifungal in the last 3m
retrospective treatment pattern survey for the patients with hypertension and stroke

Conditions: Hypertension

Summary: this study will address the treatment rate and control rate of hypertension, treatment pattern and factors that affect bp control by examining retrospective medical records of hypertension patients recovering from stroke, among outpatients coming to the neurology department in 10 university hospitals nationwide.


Eligibility criteria:
inclusion criteria: * patients had been hospitalized as a acute stroke in 2006 * patient with history of stroke receiving hypertension medication during at least 1 year. exclusion criteria: * secondary hypertension patients * patients not receiving hypertension medication

Keywords: hypertension post stroke jnc7 2007 esh-esc guidelines survey
expert-guided early tracheostomy pathway

Conditions: Respiratory Failure; Tracheostomy Complication

Summary: the optimal timing of tracheostomy insertion remains uncertain. we hypothesized that a clinical pathway including expert-informed risk assessment regarding predicted duration of mechanical (mv) would enhance the effectiveness of early percutaneous dilatational tracheostomy (pdt) for patients with anticipated prolonged durations of mv, as reflected by duration of ventilation, complications, and patient-centered outcomes.

three-year prospective observational study (2018-2020) at a tertiary care level 1 trauma center (king hussein medical center) in amman jordan and 4 affiliated subspecialty hospitals. the study sequentially enrolled all adult patients (\>18yo) with critical illness receiving mv in an intensive care unit for 48 hours or longer. institutional ethical committee clearance for the study was secured.

Eligibility criteria:
inclusion criteria: patients undergoing continued mv for 48 or more hours for whom continuation of life-prolonging therapy was indicated exclusion criteria: patients at imminent risk of death were included
evaluation of a topical treatment for actinic keratosis

Conditions: Actinic Keratosis of Face and Scalp

Summary: a topical treatment applied twice daily for 4 weeks to induce disappearance of facial actinic keratosis (ak). first 4 weeks treatment (visit 1, 2 and 3 at 0,2 an 4 weeks) treated as a double blind parallel study. from weeks 4 to 7 (visit 3 to visit 4) all patients to be treated by the active component.


Eligibility criteria:
inclusion criteria: * males or females 30 to 90 years old, inclusive, in good general health * clinical diagnosis of actinic keratosis * at least 2 clinically diagnosed, 3-15 mm ak lesions on face or scalp * patient is competent to understand and sign a consent form, and is willing and able to follow study procedures and attend all visits * female patients of childbearing potential must have a negative urine pregnancy test prior to receiving study medication * sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception * pharmacologic methods of contraception should be stable for 1 month prior to visit 1 and be maintained at same dose during the study exclusion criteria: * patients who had been treated with: 5-fu, diclofenac, retinoids, ingenol mebutate or imiquimod within 4 weeks of study, immunomodulators, or interferon/interferon inducers or systemic immunosuppressants within 8 weeks of study, cryodestruction, curettage, photodynamic therapy, surgical excision on the treatment area within 4 weeks of study, systemic cancer therapy, uva therapy, uvb therapy, laser abrasion, dermabrasion * history of hereditary angio-edema, epilepsy or parkinson's disease * erythroderma or history of immunodeficiency disorders * pregnancy, lactation or patient who is not practicing effective contraception * history of alcohol and drug abuse within 5 years of screening * known hypersensitivity or previous allergic reaction to any of the components of the study medication * having a member of the same household in the trial * patient has participated in an investigational clinical, surgical, drug or device study within the past 30 days * patients who in the opinion of the investigator should not be included in the study for any reason, including inability to follow procedures

Keywords: actinic keratosis topical dermatology treatment clinical study double blinded
collagen protein versus placebo on muscle recovery

Conditions: Anthropometrics: Height and Weight; Isometric Standing and Seated Plantarflexion; Calf Muscle Thickness; Achilles Tendon Length and Thickness; Myotonography of the Calf Musculature and Achilles Tendon; Pain Pressure Threshold of the Calf; Pain Scale; Endurance Calf Test; Dietary Analysis

Summary: this study is focused on exploring the gap in the literature by comparing the effects of collagen protein versus placebo supplementation on the musculotendinous unit following muscle damaging protocol. thus, the purpose of this study is to identify and compare the effect of collagen protein versus placebo supplementation on indirect markers of musculotendinous unit recovery following eccentric calf exercises.

various physical assessments that include pain scale, pain pressure threshold assessment, body composition, calf circumference measurements, muscle thickness measurements, achilles tendon length and thickness measurements, myotonography of the calf, isometric force assessments during standing and seated plantarflexion positions, a heel raise test, and a standardized exercise routine focused on eccentric movements, targeting a leg chosen at random. additionally, will consume a daily dose of two 30-g amount of collagen peptides derived from bovine hide (commercially available as vital proteins or peptan) or placebo (30 g of pure maltodextrin with no amino acids) mixed in 300 ml of orange gatorade zero. gatorade zero, maltodextrin, and collagen is going to be stored in the locked cabinet in the lab. research team will mix the supplement (placebo or maltodextrin) with gatorade zero in a non-clear bottle and will administer it to the participants on-site.

Eligibility criteria:
inclusion criteria: * males between the ages of 18-30 years old * determined to be healthy by par-q+ and the hhq exclusion criteria: * untrained (no resistance training in the past 3 months) * any response of "yes" on the par-q+; exclusion criteria noted on the hhq * allergy to bovine collagen or maltodextrin
exercise: addressing stress in relapse prevention for substance use disorders

Conditions: Substance Use Disorders

Summary: relapse contributes significantly to the chronicity of substance use disorders, one of the most costly medical/mental health problems facing our nation. the incorporation of exercise into relapse prevention efforts will address stress, a critical factor in relapse, provide other health benefits, and improve overall quality of life. combined, these changes will reduce the risk of relapse to substance use while also lessening the burden of this psychiatric disorder upon society

about half of all individuals who receive treatment for substance use disorders (sud) relapse within a year. stress and an individual's biological response to it are significant predictors of relapse. thus, interventions that decrease stress and normalize an individual's biological response to stress are desperately needed. exercise decreases stress and improves the body's regulation of stress. the proposed project will utilize exercise as a novel relapse prevention intervention with individuals who have recently completed inpatient sud treatment. this project will evaluate the efficacy of a motivational intervention for exercise in a randomized clinical trial of 150 sud patients beginning aftercare treatment at the va st. louis health care system. participants will be randomized to one of two interventions: (1) standard care (sc), or (2) standard care plus a motivational intervention targeting exercise that lasts for six months. participants are followed every three months for one year. results from this study will advance exercise as a new strategy for enhancing stress regulation and prevention of relapse in sud populations.

Eligibility criteria:
inclusion criteria: * undergoing residential substance use disorders treatment at va st. louis healthcare system * age 18 or older * english speaking; * substance dependence * recent substance use * does not have high blood pressure * documented physician clearance to undergo exercise testing \& exercise * plans to begin aftercare at the clinic within the next two weeks exclusion criteria: * severely disruptive behavior * serious uncontrolled psychiatric disorder * medical history in the past 6 months that contraindicates exercise * pregnancy, plans to get pregnant in the next six months. * currently breastfeeding * obese - class ii * currently taking corticosteroids or hormonal contraceptives * in recovery for pathological gambling * opiate dependence.
serum antimullerian hormone levels in patients who underwent hayman suture

Conditions: Uterine Atony With Hemorrhage; Ovarian Dysfunction

Summary: from patient charts we will review patients who had undergone cesarean section within the last 6 months and identify those who received a the hayman uterine compression suture for uterine atony. we will also select patients who delivered a baby without recieving a hayman suture to create a control group. patietns will be grouped as hayman group if they recevied a hayman suture during c/s and control group if thay had not recevied a hayman suture. we will then check patient charts for post-cesarean outpatient clinic visit and select those who received ovarian reserve evaluation via hormones and antral follicle count during the visits. finally, we are planning to investigate any correlation between hayman suture and ovarian dysfunction.

hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. it is usually employed to overcome uterine atoy dıring cesarean section. however, since the technique is relatively new, data on its safety and efficacy arelimited to a few case reports. several complications including cavity obliteration, blood entrapment and infections have been described. however, data regarding the ovarioan function is lacking.

Eligibility criteria:
inclusion criteria: * age 18- 40 years * no systemic or endocrine diseases * patients who had uterine artery ligation due to atony * healthy postpartum patients as controls exclusion criteria: * patients with polyctsitic over syndrome * pregnancy with ivf or oocyte donation * obese patients * patients with previous/present endometriosis

Keywords: cesarean section uterine atony hayman uterine compression suture follicle-stimulating hormone luteinizing hormone antral follicle count
left atrial volume index in asymptomatic aortic stenosis

Conditions: Aortic Valve Stenosis; Heart Failure

Summary: aortic stenosis results in increased filling pressures of the heart. size and function of the left atrium may be a marker for more advanced heart disease (heart failure) in patients with severe aortic stenosis, not presenting any apparent symptoms. the goal of this study is to establish the importance and possible implications of left atrial dilation in asymptomatic patients with aortic valve stenosis.

aortic valve stenosis (as) is the most common valvular disease in the western world. mild and moderate as generally is well tolerated severe as is associated with considerable morbidity and mortality. the consequence of as is increased pressure load on the left ventricle, which causes changes in the ventricular function and structure (left ventricular remodeling, hypertrophy, fibrosis). with longstanding elevated filling pressures the left atrium will dilate and heart failure symptoms will develop. when apparent, symptoms of heart failure, in as are associated with high mortality rate and aortic valve replacement (avr) is recommended. the clinical assessment of heart failure symptoms in as is however challenging particularly in the elderly, as symptoms progress slowly and may mimic age related fragility. in this observational study, the goal is to investigate the importance and possible implications of left atrial dilation and heart failure among 100 patients with asymptomatic severe aortic stenosis. participants undergo echocardiographic evaluation for diastolic heart failure and we assess myocardial fibrosis using magnetic resonance imaging and exercise testing with invasive hemodynamic monitoring (right heart catheterization). la dilatation may potentially identify patients likely benefiting of early surgery. the importance and possible implications of la dilatation in asymptomatic as patients has however not yet been established.

Eligibility criteria:
inclusion criteria: * asymptomatic severe aortic stenosis (vmax \> 3.5 m/sec and aortic valve area \< 1 cm2). exclusion criteria: * moderate lv systolic dysfunction (lvef \< 50%) * concomitant moderate-severe aortic valve regurgitation * concomitant moderate-severe mitral valve regurgitation * moderate to severe nephropathy * chronic or persistent atrial fibrillation * implanted pacemaker or cardio defibrillator * disability to exercise testing.

Keywords: aortic valve stenosis functional capacity cardiomyopathies endomyocardial fibrosis cardiovascular diseases heart diseases heart valve diseases atrial fibrillation hypertrophy hypertrophy, left ventricular diastology
comparison of patients with and without foreign body aspiration after bronchoscopy.

Conditions: Foreign Body Aspiration, Blood Gas, Bronchoscopy

Summary: to compare patients under 5 years of age with foreign body aspiration and without foreign body aspiration with radiological and blood gas results.

foreign body aspiration in children is a serious cause of mortality and morbidity. it is a preventable and treatable disease. difficulties in diagnosis arise in non-radiopaque foreign body aspirations. recently, when there is a suspicious history, bronchoscopy is recommended. bronchoscopy is used to both diagnose and treat foreign body aspiration. bronchoscopy seems to continue to be performed in suspicious cases until a method to establish a definitive diagnosis of foreign body aspirations before the operation is invented. in our study, to compare patients under 5 years of age with foreign body aspiration and without foreign body aspiration with radiological and blood gas results.

Eligibility criteria:
inclusion criteria: suspected foreign body aspiration exclusion criteria: infection, trauma
the effects of a mediterranean style diet in heart disease patients running a cardiac rehabilitation program

Conditions: Acute Myocardial Infarction With ST Elevation

Summary: nutrition is capable of altering the cardiovascular health of the general population. however, the ideal food and nutritional interventions for the secondary prevention of cardiovascular brain disease and for cardiac rehabilitation are still far from being defined, given the lack of scientific evidence in this specific population of individuals with atherosclerotic disease. this work aims to demonstrate that an intensive program will improve cardiovascular risk predictor parameters, such as high systolic blood pressure, altered lipid and glucose profile, used in the smart risk score tool. in this 12-week clinical study with two arms running in parallel, individuals referred to a cardiac rehabilitation program will receive either an intensive food and nutrition intervention program with nutrition consultations, in which the adoption of the mediterranean diet is promoted, with contacts telephone calls, short text messages, consultation support tools, podcasts, free access short videos, culinary medicine sessions and nutrition "workshops", or the standard of care program recommended in the nutritional support protocol of the cardiac rehabilitation program. at the beginning of the study, at 4 weeks, at 8 weeks and at 12 weeks, blood and urine samples will be collected, body composition, blood pressure, adherence to the mediterranean dietary pattern will be assessed, by applying the predimed questionnaire and the dietary intake of 24h previous. the quality of life of individuals will be assessed by the eq-5d-5l questionnaire at the beginning and at the end of the study. it is expected that the increased intensity and support from the intensive program will have a significant impact on the various metabolic and inflammatory markers predictive of cardiovascular risk and that these observed changes will result in a decreased 10-year risk of developing acute myocardial infarction, stroke or vascular death. on the other hand, the intervention is intended to improve quality of life, improve weight control and assess the impact it has on adherence to the mediterranean dietary pattern.


Eligibility criteria:
inclusion criteria: * men and women with st-segment elevation acute myocardial infarction undergoing primary angioplasty; * ages 30-90 years; * willing and able to provide written informed consent. exclusion criteria: * subjects with heart failure (lvef \ 125 ng / ml) on admission; * subjects with renal failure (gfr \<50 or 60 ml / min / 1.73m²); * subjects requiring internment; * subjects who present any other condition that may interfere with adherence to the study protocol. * subjects who attract to be accompanied by another nutritionist; * subjects who have a specific dietary pattern or who take vitamin and/or mineral supplements; * subjects unable to give consent.